Pharmaceutical Market Archives

Slovakia is facing political turmoil focused on health minister, Zuzana Dolinková. She survived her first no-confidence vote on 14 May, after only seven months in office. The culture minister also faced recall in back-to-back votes.

Ireland is attracting fewer clinical trials than some EU countries with similar populations and economic performances, according to a new report by the IPHA, Ireland's biopharmaceutical industry body. Denmark attracts almost three times as many industry clinical trials.

The professional standards of Hungarian healthcare providers are under scrutiny following the introduction of a new framework of healthcare regulations. An ageing population is being cared for by an ageing medical workforce.

Prioritising pollution prevention or human health? That's the question probing the ethical limits of Belgium's pharmaceutical industry, amidst discussion of whether to approve new medicines if environmental risk assessments prove inadequate.

The European Commission has open infringement procedures against Bulgaria for the long-term violation of internal market rules and illegal procedures allowing private hospitals to avoid tendering for medicines.

Eighty-five percent of Poles believe that drug prices in the country are high, according to a survey conducted by Ariadna, the Nationwide Research Panel for Health Market. Despite this perception, the prices of reimbursed drugs in Polish pharmacies are among the lowest in the EU.

The Czech Health Ministry has introduced amendments to the public insurance law to enhance healthcare accessibility and ensure sustainable medical treatment costs – a move welcomed by Czech pharmaceutical companies.

Understaffing is keeping hospital doctors far from the EU’s 11-hour rest period. In Greece, hospital administrations are breaching the 48-hour work-week rule, while in Sweden, doctors can be ordered to be on-call at home to get their regulated rest. 

Experts gathered at the EIT Health Summit for the launch of a new report ‘Implementing the European Health Data Space across Europe’, which could boost Ireland's digital healthcare transition.

Irish candidates for the upcoming European parliament elections are attending a series of health manifesto events where pharmaceutical industry experts, the press and the public are quizzing candidates’ support for innovation and sustainability.

The Belgian innovative pharmaceutical industry continues to grow, but competitiveness dynamics and EU pharma package revisions are causing uncertainty. Euractiv spoke in depth with Caroline Ven, CEO of pharma.be, about the sector's concerns.

Slovakia is still in the 'undecided' camp for the EU Pharmaceutical Package's regulatory data protection (RDP) system, but senior Slovak voices question the RDP's unpredictability and exposure to external risk.

Slovakia's Prime Minister Robert Fico, has announced a new wave of proposed cost-saving measures aimed at deficit reduction, but they risk impacting Slovakia's health service and health insurance provision.

Swedish researchers are preparing a national clinical trial with the aim to personalise off-label cancer drugs for patients who have run out of treatment options. The trial hopes to lead to a broad adoption of precision medicine in cancer care across Sweden.

Hungary has launched a new nutritional vigilance website to tackle poor data transparency for dietary supplement side effects. An expanding market and misleading advertising have increased consumer risks, which the site now seeks to counter.

Poland's pharmaceutical industry says there's still a long journey ahead for the revision of the EU's pharma legislation. Despite the Pharma Package now heading to Council, the Polish Ministry of Health chooses to remain silent.

Slovakia's much-needed hospital reforms aim to create an optimised network of categorised hospitals in Slovakia, ensuring higher quality of provided health care for patients. However, the system is plagued by delays and controversies. 

The Bulgarian parliament has adopted a decision requiring the state to pay for the treatment of some patients with rare diseases. The decision follows decades of legal battles and accusations of discrimination.

The Hungarian pharmaceutical market could be fundamentally reorganised following a government decree entrusting the supply of hospital medicines to a 'project company' with special rights. The change will take effect in January. Stakeholders are alarmed.

The first National Strategy on Quality of Care, Patient Safety, and Patient Experience is being developed in Greece. It aims to build, strengthen, and consolidate the quality of care through national policies.

A new antibiotic against gram-negative bacteria hasn’t been developed since the 1970s. Now, a European research team led by Swedish scientists has discovered multi-drug-resistant bug-killing compounds that could lead to a new class of antibiotics.

Poland's clinical trials give access to innovative therapies for over 25,000 patients, but a new Medical Research Agency survey reports half of Poles lack any real understanding of clinical trials, hindering long-term success.

A new analysis by Ernst & Young (EY) for the Czech Association of Innovative Pharmaceutical Industry (AIFP) underscores the benefits of centre-based medical care in Czechia. However, rising costs are fast straining the business model.

Bulgaria remains the only country in the EU where the death rate from oncological diseases continues to rise. Patients face financial and organisational difficulties in accessing treatment, even though public funding has more than doubled in the past five years.